Metformin Use Is Associated with Reduced Incidence and Improved Survival of Endometrial Cancer: A Meta-Analysis

BioMed Research International

Volumn 2017, Issue , 2017, Pages

  Tang, Yun Liang ^a   Zhu, Ling Yan ^a   Li, Yu ^b   Yu, Jiao ^a   Wang, Jiao ^a   Zeng, Xiang Xia ^a   Hu, Kai Xiang ^a   Liu, Jian Ying ^a   Xu, Ji Xiong ^a  

^a NANCHANG UNIVERSITY   (China)

^b Pingxiang Maternal and Child Health Care Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

CANCER INCIDENCE; CANCER SURVIVAL; DIABETES MELLITUS; DIABETIC PATIENT; DRUG USE; ENDOMETRIUM CANCER; HUMAN; META ANALYSIS; OVERALL SURVIVAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; DIABETES MELLITUS, TYPE 2; ENDOMETRIAL NEOPLASMS; FEMALE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

DIABETES MELLITUS, TYPE 2; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 85017108273     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2017/5905384     Document Type: Review

References (45)

1. R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2015, " CA Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5-29, 2015.
2. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics, " CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69-90, 2011.
3. V. M. Chia, P. A. Newcomb, A. Trentham-Dietz, and J. M. Hampton, "Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis, " International Journal of Gynecological Cancer, vol. 17, no. 2, pp. 441-446, 2007.
4. J. D. Wright, N. I. B. Medel, J. Sehouli, K. Fujiwara, and T. J. Herzog, "Contemporary management of endometrial cancer, " The Lancet, vol. 379, no. 9823, pp. 1352-1360, 2012.
5. D. M. Nathan, J. B. Buse, M. B. Davidson et al., "Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, " Diabetologia, vol. 49, no. 8, pp. 1711-1721, 2006.
6. J. Hanprasertpong, I. Jiamset, A. Geater, T. Peerawong, W. Hemman, and S. Kornsilp, "The effect of metformin on oncological outcomes in patients with cervical cancer with Type 2 diabetes mellitus, " International Journal of Gynecological Cancer, vol. 27, no. 1, pp. 131-137, 2017.
7. H. Xu, M. C. Aldrich, Q. Chen et al., "Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality, " Journal of the American Medical Informatics Association, vol. 22, no. 1, pp. 179-191, 2015.
8. S. Kumar, A. Meuter, P. Thapa et al., "Metformin intake is associated with better survival in ovarian cancer: a case-control study, " Cancer, vol. 119, no. 3, pp. 555-562, 2013.
9. S. J. Ma, Y. X. Zheng, P. C. Zhou, Y. Xiao, and H. Tan, "Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis, " Oncotarget, vol. 7, no. 40, pp. 66202-66211, 2016.
10. G. Wan, X. Yu, P. Chen et al., "Metformin therapy associated with survival benefit in lung cancer patients with diabetes, " Oncotarget, vol. 7, no. 23, pp. 35437-35445, 2016.
11. K. H. Stopsack, D. R. Ziehr, J. R. Rider, and E. L. Giovannucci, "Metformin and prostate cancer mortality: a meta-analysis, " Cancer Causes and Control, vol. 27, no. 1, pp. 105-113, 2016.
12. X.-K. He, T.-T. Su, J.-M. Si, and L.-M. Sun, "Metformin is associated with slightly reduced risk of colorectal cancer and moderate survival benefits in diabetes mellitus: a metaanalysis, " Medicine, vol. 95, no. 7, article e2749, 2016.
13. Z.-J. Zhang, Z.-J. Zheng, R. Shi, Q. Su, Q. Jiang, and K. E. Kip, "Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis, " Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 7, pp. 2347-2353, 2012.
14. N. Zhu, Y. Zhang, Y. I. Gong, J. He, and X. Chen, "Metformin and lung cancer risk of patients with type 2 diabetes mellitus: a meta analysis, " Biomedical Reports, vol. 3, no. 2, pp. 235-241, 2015.
15. H. Yu, L. Yin, X. Jiang et al., "Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies, " PLoS ONE, vol. 9, no. 12, Article ID e116327, 2014.
16. B. Viollet, B. Guigas, N. Sanz Garcia, J. Leclerc, M. Foretz, and F. Andreelli, "Cellular and molecular mechanisms of metformin: an overview, " Clinical Science, vol. 122, no. 6, pp. 253-270, 2012.
17. E. Giovannucci, D. M. Harlan, M. C. Archer et al., "Diabetes and cancer: a consensus report, " Diabetes Care, vol. 33, no. 7, pp. 1674-1685, 2010.
18. C.-H. Tseng, "Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan, " Gynecologic Oncology, vol. 138, no. 1, pp. 147-153, 2015.
19. M. Franchi, R. Asciutto, F. Nicotra et al., "Metformin, other antidiabetic drugs, and endometrial cancer risk: a nested casecontrol study within Italian healthcare utilization databases, " European Journal of Cancer Prevention, 2016.
20. E. M. Ko, P. Walter, A. Jackson et al., "Metformin is associated with improved survival in endometrial cancer, " Gynecologic Oncology, vol. 132, no. 2, pp. 438-442, 2014.
21. M. M. Al Hilli, J. N. Bakkum-Gamez, A. Mariani et al., "The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts, " Gynecologic Oncology, vol. 140, no. 2, pp. 270-276, 2016.
22. C. Becker, S. S. Jick, C. R. Meier, and M. Bodmer, "Metformin and the risk of endometrial cancer: a case-control analysis, " Gynecologic Oncology, vol. 129, no. 3, pp. 565-569, 2013.
23. J. Luo, S. Beresford, C. Chen et al., "Association between diabetes, diabetes treatment and risk of developing endometrial cancer, " British Journal of Cancer, vol. 111, no. 7, pp. 1432-1439, 2014.
24. E. M. Ko, T. Stürmer, J.-L. Hong, W. C. Castillo, V. Bae-Jump, and M. J. Funk, "Metformin and the risk of endometrial cancer: a population-based cohort study, " Gynecologic Oncology, vol. 136, no. 2, pp. 341-347, 2015.
25. N. S. Nevadunsky, A. Van Arsdale, H. D. Strickler et al., "Metformin use and endometrial cancer survival, " Gynecologic Oncology, vol. 132, no. 1, pp. 236-240, 2014.
26. A. Lemánska, M. Zaborowski, M. Spaczýnski, and E. Nowak-Markwitz, "Do endometrial cancer patients benefit from metformin intake" Ginekologia Polska, vol. 86, no. 6, pp. 419-423, 2015.
27. O. Ezewuiro, T. A. Grushko, M. Kocherginsky et al., "Association of metformin use with outcomes in advanced endometrial cancer treated with chemotherapy, " PLoS ONE, vol. 11, no. 1, Article ID e0147145, 2016.
28. V. Seebacher, B. Bergmeister, C. Grimm, H. Koelbl, A. Reinthaller, and S. Polterauer, "The prognostic role of metformin in patients with endometrial cancer: a retrospective study, " European Journal ofObstetricsGynecology and Reproductive Biology, vol. 203, pp. 291-296, 2016.
29. A. Stang, "Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies inmetaanalyses, " European Journal of Epidemiology, vol. 25, no. 9, pp. 603-605, 2010.
30. K.-M. Lee, M. Lee, J. Lee et al., "Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer, " Oncotarget, vol. 7, no. 25, pp. 38500-38512, 2016.
31. Z. Al-Wahab, I. Mert, C. Tebbe et al., "Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction, " Oncotarget, vol. 6, no. 13, pp. 10908-10923, 2015.
32. X. Xiao, Q. He, C. Lu et al., "Metformin impairs the growth of liver kinase B1-intact cervical cancer cells, " Gynecologic Oncology, vol. 127, no. 1, pp. 249-255, 2012.
33. A. Gadducci, N. Biglia, R. Tana, S. Cosio, and M. Gallo, "Metformin use and gynecological cancers: a novel treatment option emerging from drug repositioning, " Critical Reviews in Oncology/Hematology, vol. 105, pp. 73-83, 2016.
34. X. Yu, W. Mao, Y. Zhai et al., "Anti-tumor activity of metformin: from metabolic and epigenetic perspectives, " Oncotarget, vol. 8, no. 3, pp. 5619-5628, 2016.
35. S. A. Hawley, A. E. Gadalla, G. S. Olsen, and D. GrahameHardie, "The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism, " Diabetes, vol. 51, no. 8, pp. 2420-2425, 2002.
36. V. Brower, "Illuminating the diabetes-cancer link, " Journal of the National Cancer Institute, vol. 104, no. 14, pp. 1048-1050, 2012.
37. B. Jiang, X. Zhang, L.-L. Du et al., "Possible roles of insulin, IGF-1 and IGFBPs in initiation and progression of colorectal cancer, " World Journal of Gastroenterology, vol. 20, no. 6, pp. 1608-1613, 2014.
38. K. M. J. De Bruijn, L. R. Arends, B. E. Hansen, S. Leeflang, R. Ruiter, and C. H. J. Van Eijck, "Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer, " British Journal of Surgery, vol. 100, no. 11, pp. 1421-1429, 2013.
39. E. S. Schernhammer, J. M. Holly, D. J. Hunter, M. N. Pollak, and S. E. Hankinson, "Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II, " Endocrine-Related Cancer, vol. 13, no. 2, pp. 583-592, 2006.
40. R. N. Roy, A. H. Gerulath, A. Cecutti, and B. R. Bhavnani, "Discordant expression of insulin-like growth factors and their receptor messenger ribonucleic acids in endometrial carcinomas relative to normal endometrium, " Molecular and Cellular Endocrinology, vol. 153, no. 1-2, pp. 19-27, 1999.
41. E. Rozengurt, J. Sinnett-Smith, and K. Kisfalvi, "Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer, " Clinical Cancer Research, vol. 16, no. 9, pp. 2505-2511, 2010.
42. J. J. Howell, S. J. H. Ricoult, I. Ben-Sahra, and B. D. Manning, "A growing role for mTOR in promoting anabolic metabolism, " Biochemical Society Transactions, vol. 41, no. 4, pp. 906-912, 2013.
43. S. Sósnicki, M. Kapral, and L. Wglarz, "Molecular targets of metformin antitumor action, " Pharmacological Reports, vol. 68, no. 5, pp. 918-925, 2016.
44. Z.-H. Zhang, P.-Y. Su, J.-H. Hao, and Y.-H. Sun, "The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies, " International Journal of Gynecological Cancer, vol. 23, no. 2, pp. 294-303, 2013.
45. J. Xie, X. Wang, and C. G. Proud, "mTOR inhibitors in cancer therapy, " F1000Research, vol. 5, 2016.